Preview

User

Not a user? Register with this site Forgot your password?

Bulletin of Reproductive Health

Advanced search

Evolution of hormonal contraception

https://doi.org/10.14341/brh2011218-29

Abstract

Today about 80 million women prevent unintended pregnancies using oral contraceptives all over the world. Oral contraceptives have been the most investigated medicines arriving on the market. The data about their potential benefits and risks for health are updated regularly, and thе tendency, maintenance is expected. Oral contraceptives are considered as the main large achievement in reproductive medicine because they provide essential health benefits, confirmed numerous researches; serious adverse effects were observed extremely seldom. Routine risk-factor revealing in potential users of oral contraceptives significantly decreases the conditions frequency of serious adverse effects.

About the Authors

Zh A Uzhegova
Federal Endocrinological Research Center, Moscow, Russia


M A Sviridonova
Federal Endocrinological Research Center, Moscow, Russia


References

1. Прилепская В.Н. Гормональная контрацепция. М.: МЕДпресс, 1998.

2. Тирер Л.,История разработки и вывода на рынок оральных контрацептивных средств. Все о контрацепции. 2008; 4:2-5.

3. Bayer Schering Pharma. Market Research. Data on file, 2009.

4. UNFPA. Births per 1000 women (15-19 years) 2002. State of World Population 2003. Retrieved Jan 22, 2007.

5. Hatcher RA et al., editors, Contraceptive Technology, 18th rev. ed., Bridging the Gap Communications, 2004.

6. Arevalo M et al. Efficacy of a new method of family planning: the Standard Days Method. Contraception 2002; 65:333-8.

7. Arevalo M et al. Efficacy of the new Two Day Method of family planning. Fertil Steril 2004; 82:885-92.

8. Reid RL et al. Oral contraceptives and venous thromboembolism, consensus opinion from an international workshop held in Berlin, Germany, in December 2009. J Fam Pl and Repro Hlth Care 2010;36(3):117-22.

9. EMEA. Combined oral contraceptives and venous thromboembolism. The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Public Assessment Report. 28 September 2001. http://www.ema.europa.eu/pdfs/human/ regaffair/0220101e n.pdf. Accessed May 2010.

10. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.

11. Anderson FA Jr et al. Risk factors for venous thromboembolism. Circulation 2003;107:I-9-I-16.

12. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I-4-I-8.

13. Dinger JC. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 2007;75(5):344-54.

14. Heit JA et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Int Med 2005;143:697-706.

15. Suissa S et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Circulation 1997;56:141-6.

16. Suissa S et al. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15(4):817-21.

17. Information presented by Jurgen Dinger at a symposium at the 10th Congress of the European Society of Contraception (ESC), 30 April-3 May 2008, Prague, Czech Republic.

18. WHO. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-8.

19. Jick H et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.

20. Seeger JD et al. Risk of thromboembolism in women taking ethinylestradiol/dro-spirenone and other oral contraceptives. Obstet Gyn 2007;110(3):587-93.

21. Lidegaard 0 et al. Hormonal contraception and risk of venous thromboem-bolism: national follow-up study. BMJ 2009;339:b2890.

22. Van Hylckama Vlieg A et al. Effects of oestrogen dose and progestogen type on venous thrombotic risk associated with oral contraceptives: results of the MEGA case-control study. BMJ 2009:339:b2921.

23. Rosamond W et al. Heart Disease and Stroke Statistics2008 Update. A Report From the American Heart Association Statistics Commit tee and Stroke Statistics Subcommittee. Circulation 2008;117;e25-e146.

24. Ladner HE et al. Acute myocardial infarction in pregnancy and the puerperium: a population-based study. Obstet Gyn 2005;105:480-4.

25. James, AH et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006;113:1564-71.

26. Chan WS et al. Risk of stroke in women exposed to low dose COCs_a critical evaluation of the evidence. Arch Intern Med 2004;164:741-7. Review Erratum in Arch Intern Med 2005;165:2040.

27. WHO. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202-09.

28. Dunn N et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999; 318:1579-84.

29. Rosenberg L et al. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001; 161(8):1065-70.

30. Tanis BC et al. Oral contraceptives and the risk of myocardial infarction. NEJM 2001;345(25):1787-93.

31. Khader YS et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003; 68:11-7.

32. Margolis KL et al. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007; 88:310-6.

33. Key TJ et al. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.

34. ESHRE Capri Workshop Group. Hormones and breast cancer. Hum Reprod Update 2004;10(4):281-93.

35. Cancer registry of the Robert-Koch-Institute, Berlin, Germany http: // www. rki. de/cln_116/nn_204086/DE / Content / GBE / DachdokKrebs / Datenbankabfra-gen/ Neuerkrankungen/neuerkrankun-gen_node. html? _nnn=true. Accessed May 2009.

36. Key TJ et al. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.

37. Russo J et al. The protective role of pregnancy in breast cancer. Breast Cancer Res 2005;7:131-142.

38. Vessey M et al. Oral contraceptive use and cancer: Findings in a large cohort study 1968-2004. Br J Cancer 2006;95:385-89

39. Hanna L et al. Prevention of ovarian cancer. Best Pract & Res Clin Obstet Gyn 2006;20(2):339-62.

40. Rosenthal A et al. Familial ovarian cancer screening. Best Pract & Res Clin Obstet Gynecol 2006;20(2):321-38.

41. Casagrande JT et al. «Incessant ovulation» and ovarian cancer. Lancet 1979;2:170-3.

42. Cramer DW et al. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.

43. Tworoger S et al. Association of oral contraceptive use, other contraceptive methods and infertility with ovarian cancer risk. Am J Epidemiol 2007;166(8):894-901.

44. Ness RB et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group Steroids Hormones and Reproductions. Am J Epidemiol 2000;152:233-41.

45. Hannaford PC et al. Cancer among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007 [online 12 September 2007].

46. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiologi-cal studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-14.

47. McGuire V et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 2004;160:61318.

48. Whittemore AS et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004;91:1911-15.

49. Grady G et al. Hormone replacement therapy and endometrial cancer risk: a meta analysis. Obstet Gyn 1995;85:304.

50. Key TJ et al. The dose-effect relationship between 'un- opposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.

51. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997;12:1851-63.

52. Kaufman DW et al. Decreased risk of endometrial cancer among oral-contraceptive users. NEJM 1980;303: 1045-7.

53. Kelsey JL et al. A case-control study of cancer of the endometrium. Am J Epidemiol 1982;116:333-42.

54. Hulka BS et al. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 1982;247:475-7.

55. Jick SS et al. Oral contraceptives and endometrial cancer. Obstet Gyn 1993;82;931-5.

56. Weiderpass E et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84.

57. LaVecchia C et al. Oral contraceptives and cancer: An update. Drug Safety 2001;24:741-54.

58. Henderson BE et al. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-56.

59. Stanford JL et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association. J Int Cancer 1993;54:243-8.

60. Centers for Disease Control. Oral contraceptive use and the risk of endometrial cancer. JAMA 1983;249:1600-4.

61. Burkman RT et al. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gyn 2004;190:5-22.

62. Rosenblatt KA et al. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186-90.

63. Hannaford PC et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335:651-8.

64. Irwin KL. The association between oral contraceptive use and neoplasia of the cervix, vagina and vulva. In: Hannaford PC, Webb AMC, editors. Evidence-guided prescribing of the pill, The Parthenon Publishing Group, 1996:145-56.

65. Fraumeni JF et al. Cancer mortality among nuns: role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst 1969;42:455-68.

66. Fernandez E et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001 ;84(5):722-7.

67. Bosetti C et al. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009;15(5):489-98.

68. ACOG Practice Bulletin. Noncontracep-tive uses of hormonal contraception. Obstet & Gynecol 2010; 115(1):206-18.

69. Huber J et al. Noncontraceptive benefits of oral contraception. Expert Opinion Pharmacotherapy 2008; 9(13): 2317-25.

70. ESHRE Capri Workshop Group. Hormonal contraception: what is new? Hum Reprod Update 2002;8(4):359-71. IARC. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. Monographs on the evaluation of carcinogenic risks to humans, vol 91, 2007.


Review

For citations:

Uzhegova Zh.A., Sviridonova M.A. Evolution of hormonal contraception. Bulletin of Reproductive Health. 2011;(2):18-29. (In Russ.) https://doi.org/10.14341/brh2011218-29

Views: 1320


ISSN 2075-6569 (Print)
ISSN 2310-421X (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)